Yazar "Türker, Sema" için listeleme
-
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
Hacıoğlu, Muhammet Bekir; Köstek, Osman; Karabulut, Senem; Taştekin, Didem; Sezgin Göksu, Sema; Alandağ, Celal; Akagündüz, Baran; Bilgetekin, İrem; Caner, Burcu; Şahin, Ahmet Bilgehan; Yıldız, Birol; Köse, Fatih; Kaplan, Muhammet Ali; Gülmez, Ahmet; Doğan, Ender; Güven, Deniz Can; Gürbüz, Mustafa; Ergun, Yakup; Karaağaç, Mustafa; Demiray, Atike Gökçen; Türker, Sema; Sakalar, Teoman; Özkul, Özlem; Akın Telli, Tuğba; Şahin, Süleyman; Kılıçkap, Saadettin; Bilici, Ahmet; Erdoğan, Bülent; Çiçin, İrfan (Imprimatur Publication, 2020)Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah (BioMed Central Ltd, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ...